The large technology stocks continued to play a leading role, but over the summer the rally broadened. Smalland mid-caps, as well as cyclical sectors, also gained ground, adding further momentum to market breadth. Emerging markets, particularly several Asian markets, were among the biggest winners of the quarter. Even in Europe, a positive market sentiment was evident, although earnings remained weaker.
This encouraging market development took place in an environment that was by no means free of burdens. On 1 August, Switzerland’s National Day, the United States
imposed drastic punitive tariffs of 39 per cent on Switzerland and the Federal Council faced the difficult task of finding economic and diplomatic responses to the new situation. A key reason for the moderate market reaction was the “front-loading effect”: many American companies had accelerated imports before the higher tariffs came into force and had built up inventories. This cushioned the short-term impact, although higher costs are likely to become apparent later in production and prices.
On 1 October, the next escalation came into effect: President Trump introduced import tariffs of 100 per cent on original pharmaceuticals. Exempt are companies with production sites in the United States or those already concretely planning to build them. This means that Roche and Novartis will not be directly affected. However, alongside the issue of production location, pricing pressure on the sector also remains. Already in the summer, Trump had called on leading pharmaceutical groups, including Roche and Novartis, to lower drug prices in the United States.
According to the OECD and UBS, the sharp increase in tariffs in the United States is beginning to show their first effects on the real economy. Companies are increasingly
faced with the choice of passing on higher import costs to consumers or reducing their margins. Both options dampen demand and employment. Private consumption has so far proved surprisingly resilient, but the strains are expected to become increasingly visible
step by step.
In September, The US Federal Reserve (Fed) resumed its cycle of monetary easing after a pause of several months (last cut Dec. 2024). Chairman Powell justified the interest rate cut with a marked cooling in the labour market. Inflation remained above target level, but the risks to employment and growth outweighed this. The Neue Zürcher Zeitung spoke of an “acid test” for the central bank, which on the one hand is exposed to political pressure from the Trump administration and on the other must preserve its credibility and independence. Markets reacted with relief, as the continuation of rate cuts is expected to support economic activity.
In Europe, structural weaknesses became more apparent. Following the fall of the government, France slid into a political crisis, which drove up French government bond yields and once again called the stability of the euro area into question. At the same time, the OECD lowered its growth forecast for Germany to 0.3 per cent, reinforcing scepticism about the resilience of the eurozone.
While markets were largely driven by monetary policy measures and economic resilience, valuations moved increasingly into focus. Technology stocks, which still account for a large share of the gains, drew attention for their elevated price levels.